42.
But national doesnt have to mean that. National could mean interprovincial provinces combining efforts to create one body.
Either way, one benefit of a national organization would be to negotiate better prices, if possible, with drug manufacturers. Instead of having one province or a series of hospitals within a province negotiate a price for a given drug on the provincial list, the national agency would negotiate on behalf of all provinces.
Rather than, say, Quebec, negotiating on behalf of seven million people, the national agency would negotiate on behalf of 31 million people. Basic economics suggests the greater the potential consumers, the higher the likelihood of a better price.
43.
A small step has been taken in the direction of a national agency with the creation of the Canadian Coordinating Office for Health Technology Assessment, funded by Ottawa and the provinces. Under it, a Common Drug Review recommends to provincial lists which new drugs should be included. Predictably, and regrettably, Quebec refused to join.
A few premiers are suspicious of any federal-provincial deal-making. They just want Ottawa to fork over additional billions with few, if any, strings attached. Thats one reason why the idea of a national list hasnt gone anywhere, while drug costs keep rising fast.
44.
【水木艾迪:阅读理解冲刺之新题型一】相关文章:
最新
2016-10-18
2016-10-11
2016-10-11
2016-10-08
2016-09-30
2016-09-30